On October 29, 2025 Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereinafter referred to as "Valerio Therapeutics" or the "Company," a biotechnology company specializing in the development of innovative drug candidates from its proprietary V-Body and integrated chemistry technology platforms, reported the publication of its 2025 half-year financial report.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2025 half-year report is available to the public on the Company’s website, under the Investors / Financial Information section.

In the first half of 2025, Valerio Therapeutics completed its strategic transformation, marked by the discontinuation of all clinical activities, including the VIO-01 trial, in order to focus its resources on preclinical R&D.

This repositioning is based on two differentiated proprietary platforms:

V-Body, derived from the acquisition of Emglev Therapeutics and developed within the subsidiary Valour Bio, dedicated to the generation of humanized single-domain antibodies (sdAbs) for various therapeutic modalities (ADCs, CAR-T sdAbs, V-Body–oligonucleotide conjugates);
The integrated chemistry platform, designed to combine biological and chemical approaches to produce next-generation immunoconjugates.
Together, these two platforms now form the foundation of the Company’s value creation strategy, focused on the discovery of innovative, partnership-ready preclinical candidates with high therapeutic potential.

(Press release, Valerio Therapeutics, OCT 29, 2025, View Source [SID1234661830])